Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2015-06-16 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about a presentation at the 2015 BIO International Convention. The document is short (2270 characters) and primarily serves as a regulatory filing to report current information rather than a full financial report or detailed presentation. It does not contain financial statements or detailed analysis, nor is it an announcement of voting results, management changes, or capital updates. The Form 6-K is a periodic report used by foreign private issuers to disclose material information. Given the nature and length of the document, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2015-06-16 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about hosting a conference call to review positive Phase III top-line results. The document is short (2330 characters) and primarily serves as an announcement of the press release and conference call, not the full transcript or detailed financial report. Form 6-K filings typically provide current reports or announcements by foreign private issuers. Given the content and length, this document is best classified as a Regulatory Filing (RNS) because it is an announcement/report filing that does not contain detailed financial statements or full call transcripts, nor is it a full annual or interim report.
2015-06-15 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing submitted by a foreign private issuer, RedHill Biopharma Ltd., to the SEC. It includes a press release about meeting a primary endpoint in a Phase III study, which is typical content for a Form 6-K. The document is short (2308 characters) and does not contain detailed financial statements or comprehensive financial analysis. It is not an annual report, quarterly report, or earnings release. Form 6-K filings are periodic reports for foreign private issuers to disclose material information and are generally classified under Regulatory Filings (RNS) in this taxonomy. Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-06-15 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about the completion of patient enrollment in a Phase IIa study, which is typical content for a Form 6-K. The document is short (2316 characters) and primarily serves as a regulatory update rather than a full financial report or detailed presentation. Form 6-K filings are periodic reports for foreign private issuers to disclose material information and are classified under Regulatory Filings (RNS) in this taxonomy. There is no detailed financial data, management discussion, or other report content that would justify classification as an Annual Report, Interim Report, or Earnings Release. Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-06-09 English
SC 13G
Major Shareholding Notification
2015-06-08 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing submitted by a foreign private issuer, RedHill Biopharma Ltd., pursuant to SEC rules. It includes a press release about completing treatment of the last patient in a Phase III study. The document is short (2280 characters) and primarily serves as a regulatory update rather than a full financial report or detailed filing. It does not contain financial statements or detailed analysis, nor is it an announcement of voting results, management changes, or capital activities. Form 6-K filings are typically periodic reports for foreign issuers to disclose material information. Given the nature and length, this fits best under Regulatory Filings (RNS) as a general regulatory announcement and update.
2015-06-08 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.